undamentalytics Newsletter

Sullivan John James: insider trades

Chief executive, Director at Mesa Laboratories Inc. No open-market purchases and 16 sales not made under a pre-set plan, reported from August 15, 2013 to August 17, 2026.

What happened after Sullivan John James’s sales?

After their sales, the shares moved −9.8% against the index over 12 months on average (a negative figure means selling was the right call); 80% trailed it.

With 296 insiders tested, some will look skilled or unskilled by chance alone: when we replaced each insider’s stocks with random companies bought on the same days, about 5.7 cleared the bar ahead and 23.3 behind. One record on its own proves little.

Trade by trade

Sullivan John James: trades against the S&P 500 afterwards
MeasuredTrades countedAverage vs S&P 500MedianWent the right wayYearst-statisticp-valueEvidence
Purchases, 3 months after the report 0 — — — — — — Not enough years
Purchases, 6 months after the report 0 — — — — — — Not enough years
Purchases, 12 months after the report 0 — — — — — — Not enough years
Purchases, 12 months after the trade 0 — — — — — — Not enough years
Sales, 3 months after the report 15 −0.8% +1.4% 47% 9 −1.05 0.32 No reliable evidence
Sales, 12 months after the report 15 −9.8% −16.7% 80% 9 −1.51 0.17 No reliable evidence
Sales, 12 months after the trade 15 −8.9% −12.9% 87% 9 −1.43 0.19 No reliable evidence

“Average vs S&P 500” is the stock’s return including dividends minus the index’s over the same dates, from the close on the first trading day after the report, or from the close on the trade date. Only windows that have finished are counted. For sales, a negative figure means the stock lagged after it was sold, so selling was the right call (green). “Went the right way” is the share of purchases that beat the index, or of sales that trailed it. The t-statistic uses one average per year of reports, because one person’s trades bunch into the same stock and weeks, and needs trades in at least four different years; the p-value comes from the t distribution with that number of years (with four years, a t of 2 has p = 0.14). “Some evidence” means p under 5%, “strong evidence” p under 1% over at least six years.

Companies traded

CompanyTitle on the latest filingPurchasesSalesFirst reportLatest report
Mesa Laboratories Inc MLAB President and CEO016August 15, 2013August 17, 2026

Trades and what followed

Moves are against the S&P 500; green means the trade went the insider’s way.

ReportedTradedCompanyTradeValue3 months after report12 months after report12 months after trade
August 17, 2026August 13, 2026 MLAB Sale $800,090 not yetnot yetnot yet
June 13, 2022June 7, 2022 MLAB Sale $1,078,690 −20.8%−47.3%−41.0%
August 17, 2021August 16, 2021 MLAB Sale $1,413,055 +6.1%−26.0%−22.6%
June 9, 2021June 8, 2021 MLAB Sale $1,340,522 −4.5%−16.7%−18.1%
November 12, 2020November 11, 2020 MLAB Sale $340,450 −10.4%−22.8%−16.1%
February 27, 2020February 27, 2020 MLAB Sale $435,746 +7.2%−17.3%−19.9%
February 27, 2020February 25, 2020 MLAB Sale $2,473,568 +7.2%−17.3%−21.2%
June 15, 2018June 15, 2018 MLAB Sale $2,364,240 −15.1%+2.8%−0.6%
February 20, 2018February 15, 2018 MLAB Sale $552,000 +19.6%+66.4%+66.0%
February 21, 2017February 17, 2017 MLAB Sale $1,133,179 +18.3%−5.5%−7.4%
February 15, 2017February 13, 2017 MLAB Sale $734,269 +12.9%−6.3%−10.4%
June 23, 2016June 22, 2016 MLAB Sale $486,520 −10.7%−5.2%−1.5%
November 9, 2015November 6, 2015 MLAB Sale $271,176 −15.2%+3.7%+3.6%
February 26, 2014February 25, 2014 MLAB Sale $870,100 −11.9%−30.5%−30.3%
August 20, 2013August 19, 2013 MLAB Sale $389,220 +1.4%−16.8%−12.9%
August 15, 2013August 14, 2013 MLAB Sale $371,520 +4.0%−8.9%−1.5%

Open-market purchases and sales of at least $10,000 in companies we cover, from SEC Form 4 filings; sales made under a pre-set Rule 10b5-1 plan are not shown. “Not yet” means the window has not finished or the share price was under $5 at entry. These are the shares’ moves after each trade: they say nothing about why Sullivan John James traded and do not suggest the use of non-public information. How every insider compares · the insider trading backtest.